Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
(2025) Journal for ImmunoTherapy of Cancer — Vol. 13, n° 3, p. e009364 (2025)
Files
e009364full.pdf
Open Access - Adobe PDF
- 1.09 MB
Details
- Authors
Nassar, Amin H 
- Abstract
- Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Results Among 110 pts, median age at ICI initiation was 65 (IQR: 59–75). Median follow-up time since ICI initiation was 36 (95% CI: 26 to 51) months. Melanoma (38%, n=42) and non-small cell lung cancer (24%, n=26) were the most common. 68 (62%) patients received ICIs as first-line, and 29 (26%) patients were treated with combination anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen 4. The most common location of cardiac metastasis was in the atria (37%, n=41) and ventricles (35%, n=39). 15 patients (13.6%) had bilateral cardiac/pericardial metastasis, 44 (40%) had left-sided, and 43 (39.8%) had right-sided. At ICI initiation, 21% (n=23) had a cardiac thrombus. Cardiology referrals and cardiac MRIs
- Affiliations
Citations
Nassar, A. H., Abou Alaiwi, S., El Zarif, T., Denu, R., Macaron, W., Abdel-Wahab, N., Freeman, D., Vasbinder, A., Hayeck, S., Anderson, E., Goodman, R. S., Johnson, D. B., Grynberg, S., Shapira, R., Kwan, J. M., Woodford, R., Long, G. V., Haykal, T., Dent, S., et al. (2025). Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal for ImmunoTherapy of Cancer, 13(3), e009364. https://doi.org/10.1136/jitc-2024-009364 (Original work published 2025)